Development of a customed designed oxygenation system combined with novel therapy to treat reperfusion injury following Neurovascular Thrombectomy.

再灌注损伤自相矛盾地加剧细胞功能障碍和死亡，血流恢复到先前的缺血组织，机械血栓切除后。血流恢复是挽救缺血组织的强制性措施。然而，再灌流可损害心、肺、肾、肠、骨骼肌、脑等一系列器官的功能/活性，甚至导致L多系统器官衰竭。再灌注损伤是一个多因素的过程，导致大量危及生命的组织破坏。尽管再灌注损伤的发生率很高，相关的死亡率/发病率/医疗负担也很高，但目前还没有有效的治疗方法来最大限度地减少血栓切除术后的RI。身体自身的修复机制是从缺血状态中恢复所依赖的全部。治疗药物的使用已经失败，因为血液的破坏作用超过了好处。Cerefuse Medical的目标是在缺血性中风的医疗设备干预方面带来下一代。再灌注损伤的机制对科学来说并不新鲜，但直到现在，随着中风护理中实现了足够的血运重建率，才有可能将这种改变患者生命的疗法带给患者。以前使用治疗药物的尝试未能减少大脑中的再灌注损伤。造成这种情况的一个因素可能是由于全血重新注入到缺血后的组织中，组织中存在有毒离子和自由基。简而言之，血液的破坏作用大于治疗剂的益处。Cerefuse的破坏性方法旨在降低组织功能，而不依赖药物对组织产生影响(尽管它们将被用于改变血液的盐分分布)。通过这个项目，Cerefuse将*设计/组装能够成功修改血液参数的功能原型设备，*设计和实施初步的动物研究，以证明在减少RI发生方面的安全性和有效性。*开发体外模型来评估血液参数*准备监管批准战略*巩固IP地位

Reperfusion Injury paradoxical exacerbation of cellular dysfunction and death, post blood flow restoration to previously ischaemic tissues, post mechanical thrombectomy. Blood flow restoration is mandatory to save ischaemic tissues. However, reperfusion could compromise function/viability of range-of-organs such as heart, lung, kidney, gut, skeletal muscle and brain on their own or even cause l multi-system organ failure. Reperfusion injury is a multi-factorial process resulting in substantial life-threatening tissue destruction.Despite of its high occurrence and related mortality/morbidity/healthcare-burden, there is no treatment available to minimise RI post thrombectomy. Body's own repair mechanisms are all that is relied-upon to recover from the ischemic state. Use of therapeutics have failed as the damaging effect of the blood outweighs benefitsCerefuse Medical aims to bring about the next generation in medical device interventions for ischemic stroke. The mechanism of Reperfusion Injury isn't new to science but it is only now, with sufficient revascularisation rates achieved in stroke care that it is possible to bring this life changing therapy to patients.Previous attempts to use therapeutics have failed to reduce reperfusion injury in the brain. A contributing factor for this is likely the presence of toxic ions and free radicals in the tissue from the reintroduction of whole blood to the post ischemic tissue. In simple terms the damaging effect of the blood outweighs the benefits of the therapeutic agent.Cerefuse's disruptive approach aims to reduce tissue function without relying on pharmaceutical agents to have an effect on tissue (though they will be used to modify the salt profile of the blood).Through this project, Cerefuse will* Design/assemble functional prototype device that can successfully modify the blood parameters,* Design and implement an initial animal study to show safety and efficacy in minimising RI occurrence.* Develop _in-vitro_ models to evaluate blood parameters* Prepare regulatory-approvals-strategy* Solidify IP position